Maybe that also(in regards to the anti-takeover), however in order for the TriKE platform for both solid and liquid tumors to enter the clinic, they will need to raise cash. (This is why the will need to sell additional shares.)
I don't know what company Pfizer bought for 30 billion, however I can GUARANTEE you that if they paid 30 billion for them. The company must already have drugs on the markets plus currently filing NDA for new drugs plus multiple drugs in phase 2/3 in the pipeline.
I'm sorry but the chance of Oxis selling for anywhere near 30 billion is nil. Sorry I'm hoping for the best too, but 30will never happen.
Here are my thoughts in regards to Oxis being acquired by Pfizer
1-2 billion assuming either OXS-1550 or OXS-3550 is approved for liquid tumors
2-3 billion assuming either OXS-1550 or OXS-3550 is approved for liquid tumors and the CNS drugs are approved.
Best case scenario and again won't actually happen, 10+ billion assuming TriKE platform shows efficacy for both liquid and solid tumors. (Essentially curing cancer) And the CNS drugs they acquire are approved.
For the reverse split, unless the stock price of OXIS gets above $0.5 in the near term (the only way this would happen is if data from OXS-1550 is stelar) there will be anywhere from a 1-50 to 1-300.
Side note, if the multiple myeloma drug ever enters the clinic and the data looks promising. Consider MCET because MCET is entitled to 3% of sale royalties from the multiple myeloma drug. However until/unless that happens, don't invest in MCET as of right now the company is worthless.
Just curious, what is your current cost per share for oxis, you don't have to tell me how many shares you have.
